From ClingantryAI Health Regulator News

The FDA has finalized a rule classifying cardiovascular machine learning-based notification software as a Class II medical device. Published in the Federal Register on September 11, 2026, the order is effective the same day, and this action places the software under special controls rather than the stricter Class III pathway. The agency states this classification provides reasonable assurance of safety and effectiveness while reducing regulatory burdens to improve patient access. Healthcare organizations using or deploying this type of AI-driven notification tool should review the specific special controls identified in the rule to ensure compliance. This final rule applies to manufacturers and developers of these cardiovascular devices.

The FDA has authorized over a thousand AI-enabled medical devices, but its first comprehensive rulebook for how these devices should be designed, validated, and monitored over their whole life — published as a draft in January 2025 — has still not been finalized. Why a hospital should care: once final, it will shape what documentation and ongoing performance monitoring you can demand from device vendors, especially for AI tools whose behavior changes with updates. Reasonable ask of vendors today: whether they're already building to the draft guidance rather than waiting.